202 COUSTEAU PLACE, DAVIS, X1
Approval of 2026 Omnibus Equity Incentive Plan at Annual Meeting
Arcadia Biosciences Receives Nasdaq Delisting Notice Due to Equity Shortfall
Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
Annual Report to Security Holders
News
Material disclosure
Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Consolidated Balance Sheets (Unaudited)
Q2
Q1
Amended Annual Report
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload
Registration of Securities under Section 12(g)